Trial · NCT00081939
UARK 2003-33, Total Therapy III
NCT00081939, Phase 2, Completed, University of Arkansas; results first posted 2015-10-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. UARK 2003-33, Total Therapy III. Trials, record NCT00081939. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00081939
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- UARK 2003-33, Total Therapy III
- NCT number
- NCT00081939
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 303 participants, actual
- Lead sponsor
- University of Arkansas
- Conditions
- Multiple Myeloma
- Interventions
- Velcade, Thalidomide
- First posted
- 2004-04-29
- Last updated
- 2017-10-17
- Results first posted
- 2015-10-21
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With Progression-Free Survival (PFS) at 3 Years From Initiation of Study Treatment | 3 years | In patients with no confirmed Partial Response, Near Complete Response, or Complete Response, progression was defined as a \>25% increase from baseline in myeloma protein production or other signs of disease progression such as hypercalcemia, etc. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With Progression-Free Survival (PFS) at 3 Years From Initiation of Study Treatment | 3 years | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Progression-Free Survival (PFS) at 3 Years From Initiation of Study Treatment | Study Treatment | 77 | percentage of participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Study Treatment | 303 | |
| Overall Study | COMPLETED | Study Treatment | 303 | |
| Overall Study | NOT COMPLETED | Study Treatment | 0 |
Source ClinicalTrials.gov
Adverse events452
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Grade 1 Allergic reaction/hypersensitivity | Immune system disorders | Study Treatment | 69 | 303 | |
| other | Grade 2 Allergic reaction/hypersensitivity | Immune system disorders | Study Treatment | 27 | 303 | |
| other | Grade 1 Rhinitis | Immune system disorders | Study Treatment | 43 | 303 | |
| other | Grade 2 Rhinitis | Immune system disorders | Study Treatment | 19 | 303 | |
| other | Grade 1 Auditory/ear-other | Ear and labyrinth disorders | Study Treatment | 16 | 303 | |
| other | Grade 2 Hearing w/o monitoring program | Ear and labyrinth disorders | Study Treatment | 16 | 303 | |
| other | Grade 2 Tinnitus | Ear and labyrinth disorders | Study Treatment | 31 | 303 | |
| other | Grade 2 Anemia | Blood and lymphatic system disorders | Study Treatment | 112 | 303 | |
| other | Grade 1 Ventricular Arrythmia | Cardiac disorders | Study Treatment | 52 | 303 | |
| other | Grade 2 Ventricular Arrythmia | Cardiac disorders | Study Treatment | 58 | 303 |
1 to 10 of 452Source ClinicalTrials.gov
See all 452 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Study Treatment | ||
| Total, other adverse events | Study Treatment | 303 | 303 |
| Total, serious adverse events | Study Treatment | 303 | 303 |
Source ClinicalTrials.gov
Papers9
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00081939
GET https://conductscience.org/api/trials/v1/NCT00081939/events?page=2